Huntington’s Disease Market

1. Huntington’s Disease Market Huntington’s disease is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain. It deteriorates a person’s physical and mental abilities usually during their prime working years and has no cure. DelveInsight's "Huntington's Disease Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Huntington's Disease, historical and forecasted epidemiology as well as the Huntington's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Huntington's Disease Overview Huntington’s disease is a hereditary neurodegenerative disorder caused by mutation in the HTT genes. The HTT mutation that causes Huntington disease involves a DNA segment known as a CAG trinucleotide repeat. This segment is made up of a series of three DNA building blocks (cytosine, adenine, and guanine) that appear multiple times in a row. An increase in the size of the CAG segment leads to the production of an abnormally long version of the huntingtin protein. The elongated protein is cut into smaller, toxic fragments that bind together and accumulate in neurons, disrupting the normal functions of these cells. The dysfunction and eventual death of neurons in certain areas of the brain underlie the signs and symptoms of Huntington disease. Huntington’s Disease symptoms 1. Personality changes 2. Mood swings 3. Depression

2. 4. Forgetfulness 5. Impaired judgment 6. Unsteady gait 7. Involuntary movements (chorea) 8. Slurred speech 9. Swallowing difficulties 10. Significant weight loss The DelveInsight Huntington's Disease market report gives a thorough understanding of the Huntington's Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. Request for sample pages of the report: https://www.delveinsight.com/sample- request/huntingtons-disease-market Huntington's Disease Epidemiology Huntington’s disease (HD) is an inherited neurodegenerative disorder caused by a CAG triplet repeat expansion in the gene encoding huntingtin. HD is clinically characterized by a variable phenotypic expression of motor, cognitive and psychiatric symptoms, with typical age-at-onset in the thirties or forties and a slow disease progression The Huntington's Disease epidemiology division provide insights about historical and current Huntington's Diseasepatient pool and forecasted trend for every seven major countries. Key Findings 1. According to a study by Swierzewski et al.titled “Huntington’s Disease Overview, Incidence and Prevalence of HD,” one in every 10,000 persons— nearly 30,000 in the United States—have Huntington's disease. Juvenile Huntington's occurs in approximately 16% of all cases. 2. As per a study, the highest prevalence rates are reported for Western populations from Europe, where the minimum prevalence is >5 per 1,00,000. The minimum HD prevalence is estimated to be 0.1–0.5 per 1,00,000 in Japan. As per the analysis, it is observed that the HD is more common in the European countries than the other countries in the 7MM. Click here and get access to a sample report. Huntington's Disease Key pharma players involved: 1. Hoffmann-La Roche 2. EIP Pharma

3. 3. Vaccinex Huntington's Disease Emerging Therapies 1. RG6042 2. Neflamapimod 3. Pepinemab Huntington's Disease Market Outlook According to the National Organization for Rare Diseases (NORD), Huntington's disease is a genetic, progressive, neurodegenerative disorder characterized by the gradual development of involuntary muscle movements affecting the hands, feet, face, and trunk, and progressive deterioration of cognitive processes and memory (dementia). Currently, the market holds no treatment options for curing Huntington’s disease. However, there are effective treatments that support Huntington’s disease, including moving disorder, psychiatric disorders, and psychotherapy. Medication management is likely to evolve over the course of the disease, depending on the overall treatment goals. Expected launch of the upcoming therapies shall fuel the growth of the market during the forecast period, i.e., 2020–2030. The Huntington’s Disease market size shall grow during the forecast period owing to the launch of upcoming therapies. The market size is expected to increase during the study period. According to DelveInsight, Huntington's Disease market in 7MM is expected to change in the study period 2017-2030. Visit our repository of reports @ https://www.delveinsight.com/report-store.php